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Most current articleGut-homing lymphocytes that express the integrin a4b7 and CCR9 might contribute to devel-
opment of primary sclerosing cholangitis (PSC). Vedolizumab, which blocks the integrin a4b7,
is used to treat patients with inflammatory bowel diseases (IBD), but there are few data on its
efficacy in patients with PSC. We investigated the effects of vedolizumab in a large international
cohort of patients with PSC and IBD.METHODS: We collected data from European and North American centers participating in the Interna-
tional PSC Study Group from patients with PSC and IBD who received at least 3 doses of
vedolizumab (n [ 102; median vedolizumab treatment duration, 412 days). Demographicr: ALP, alkaline phosphatase; ALT, alanine
aminotransferase; CD, Crohn’s disease;
ase; IQR, interquartile range; LT, liver
clerosing cholangitis; UC, ulcerative coli-
d; ULN, upper limit of normal.
© 2020 by the AGA Institute. Published by Elsevier, Inc. This is an open
access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).
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180 Lynch et al Clinical Gastroenterology and Hepatology Vol. 18, No. 1and clinical data were collected from baseline and during the follow-up period (until liver
transplantation, death, or 56 days after the final vedolizumab infusion). We analyzed overall
changes in biochemical features of liver and proportions of patients with reductions in
serum levels of alkaline phosphatase (ALP) of 20% or more, from baseline through last
follow-up evaluation. Other endpoints included response of IBD to treatment (improved,
unchanged, or worsened, judged by the treating clinician, as well as endoscopic score) and
liver-related outcomes.RESULTS: In the entire cohort, the median serum level of ALP increased from 1.54-fold the upper limit
of normal at baseline to 1.64-fold the upper limit of normal at the last follow-up examination
(P [ .018); serum levels of transaminases and bilirubin also increased by a small amount
between baseline and the last follow-up examination. Serum levels of ALP decreased by 20%
or more in 21 patients (20.6%); only the presence of cirrhosis (odds ratio, 4.48; P [ .019)
was independently associated with this outcome. Of patients with available endoscopic data,
56.8% had a response of IBD to treatment. Liver-related events occurred in 21 patients
(20.6%), including bacterial cholangitis, cirrhosis decompensation, or transplantation.CONCLUSIONS: In an analysis of patients with PSC and IBD in an international study group, we found no evi-
dence for a biochemical response to vedolizumab, although serum level of ALP decreased by
20% or more in a subset of patients. Vedolizumab appears to be well tolerated and the overall
response of IBD was the same as expected for patients without PSC.Keywords: Cholestatic Liver Disease; Ulcerative Colitis; Crohn’s Disease; Integrin alpha4beta7.See editorial on page 51.
The close association of primary sclerosing chol-angitis (PSC) with inflammatory bowel disease
(IBD) has long suggested that common pathophysiolog-
ical mechanisms acting in the liver and intestine could be
found and targeted therapeutically. Although liver disease
and intestinal inflammation in PSC can progress along
apparently independent courses, they also influence one
another, such as increased post-transplant PSC recur-
rence in patients who have a pouch or intact colon1 and
the increased risk of colorectal cancer in patients with
IBD with PSC as compared with IBD alone.2 Furthermore,
the phenotype of IBD in PSC has particular characteristics,
such as involvement of the entire colon with right-sided
dominance, ileal inflammation, and relative rectal sparing.
Some investigators suggest that the IBD associated with
PSC is its own distinct entity separate from ulcerative co-
litis (UC) or Crohn’s disease alone (CD).3-6 However,
despite recent advances in the characterization of PSC
and the IBD associated with PSC, no proven beneficial
medical therapy is available to slow the progression to
advanced liver disease and/or malignancy, and the prog-
nosis of patients with PSC remains guarded.7
In contrast, there are several effective treatments for
IBD, including recently developed targeted biologic
therapies. One such is vedolizumab, which blocks the
a4b7 integrin, and is effective in CD and UC.8 Several
studies suggest that the particular gut-homing pathway
that vedolizumab targets (namely the interaction be-
tween a4b7 and its ligand, mucosal addressin cellular
adhesion molecule-1) is implicated in the pathophysi-
ology of PSC.9-11 This includes overexpression of mucosaladdressin cellular adhesion molecule-1 in the PSC hepatic
endothelial cells, and related integrins and chemokine
ligands, which can promote a4b7/mucosal addressin
cellular adhesion molecule-1 interactions, such as
vascular adhesion protein-1 and CC-chemokine ligand 25,
respectively.10,12 Therefore, it is possible that vedolizu-
mab may play a role in reducing lymphocyte infiltration
into the liver in patients with PSC and thereby in reducing
hepatic and biliary inflammation. Indeed, it has been
shown that vedolizumab can induce clinical remission in
rheumatologic extraintestinal manifestations of IBD.13
This hypothesis has not been tested in clinical trials,
although a few observational studies published
recently document the clinical experience of treating
patients who have PSC and IBD with vedolizumab.14
These cohorts are usually limited to a small number
of centers, leading to a small sample size. We sought to
contribute to this literature by documenting our
experience in a larger international cohort of patients
with PSC and IBD.Methods
Patient Cohort
A retrospective analysis was carried out on patients
with PSC and IBD receiving vedolizumab as indicated for
their IBD (UC, CD, or IBD-unspecified). Investigators
from 20 centers across Europe and North America who
are active members of the International PSC Study Group
contributed patient data (Supplementary Table 1). To be
eligible for inclusion in the dataset, patients must have
been diagnosed with PSC according to internationally
What You Need to Know
Background
Aberrant expression of adhesion molecules in the
liver and abnormal lymphocyte trafficking are
January 2020 Vedolizumab for PSC-IBD 181accepted guidelines,15 have received a minimum of 3
doses of vedolizumab for their IBD, have baseline (pre-
vedolizumab) and follow-up blood tests including liver
biochemistry, have commenced vedolizumab with their
native liver still in situ, and received vedolizumab ac-
cording to the usual dosing schedule as licensed.16thought to be involved in the pathogenesis of pri-
mary sclerosing cholangitis (PSC). Few studies have
evaluated the effects of integrin inhibitors such as
vedolizumab in patients with PSC.
Findings
In analyses of serum samples from patients in a large
international uncontrolled study, we found that pa-
tients with PSC and IBD treated with vedolizumab
had a small increase in liver enzymes and bilirubin
levels at end of the follow-up period. However, one-
fifth had a significant reduction in level of alkaline
phosphatase regardless of use of ursodeoxycholic
acid. The endoscopic response of IBD in patients
with PSC and IBD did not differ significantly from
that reported for patients with only IBD.
Implications for patient care
Although we did not find evidence for a biochemical
response to vedolizumab in patients with IBD and
PSC, the response was heterogeneous—a subset of
patients might benefit from therapy. Vedolizumab
seems to be safe in patients with PSC and IBD.Outcomes
The effect of vedolizumab on progression of PSC was
evaluated by analyzing the change in liver biochemistry
from baseline to various time points when on vedolizu-
mab. This was done in 2 ways.
First, we analyzed the overall change in alkaline
phosphatase (ALP), alanine aminotransferase (ALT),
aspartate aminotransferase (AST), and bilirubin levels
at baseline, Week 6 (ie, Day 42), Week 14 (ie, Day 96),
and last follow-up while on vedolizumab. For further
details on the time-points collected, see the
Supplementary Methods.
Second, we deduced the proportion of patients whose
ALP dropped by 20% or more from baseline to last
follow-up. This proportionate drop was chosen because
it was believed to represent a drop of ALP of a larger
magnitude than what would usually be considered to
occur as part of the natural history of the disease and
therefore considered clinically significant.17 We also
calculated the proportion of patients whose ALP rose by
20% from baseline to last follow-up, and those whose
ALP remained stable (ie,  20%).
We sought to collect endoscopic IBD response,
classified as improved, or unchanged/worsened (as
judged by the treating clinician), and endoscopic scores
at baseline and on vedolizumab where available,
namely the Mayo Endoscopic Subscore,18 the Ulcerative
Colitis Endoscopic Index of Severity,19 and the Simple
Endoscopic Score for Crohn’s Disease.20 We also looked
at whether there was an association between endo-
scopic IBD response and change in ALP at last follow-
up using the univariate analyses described later.
Finally, we collected liver-related outcomes, which
included any of the following: listing for liver trans-
plantation (LT), undergoing LT, ascending cholangitis, new-
onset ascites, variceal bleed, hepatic encephalopathy,
cholangiocarcinoma, and death.Statistical Analyses
Paired Student t tests or Wilcoxon matched-pairs
signed rank tests were used according to whether the
data was distributed parametrically or nonparametrically,
respectively. Univariate logistic regression and multivar-
iate logistic regression were carried out to assess the
impact of relevant variables on ALP changes from baseline
to last follow-up. The Supplementary Methods provide
detailed information on statistical analyses.Results
Baseline Demographics
Of 133 patients whose data were contributed, 102
patients met inclusion criteria for the study. Reasons for
exclusion were incomplete ALP data (n ¼ 15), first dose of
vedolizumab received after LT (n ¼ 13), and less than 3
doses of vedolizumab administered (n ¼ 3). Table 1
summarizes baseline demographics, clinical, and labora-
tory information for the 102 study subjects: 64/102
(62.8%) were male, and most patients had classical large-
duct PSC (90.2%). One-fifth of patients had cirrhosis at
baseline, and most patients had associated UC (64.7%).
The median duration of vedolizumab treatment was
412 days (interquartile range [IQR], 180–651; range,
37–2609). See Supplementary Results for further infor-
mation re vedolizumab duration, follow-up, and time-
points of last follow-up liver biochemistry variables.
Forty-four patients discontinued use of vedolizumab,
predominantly for lack of efficacy (72.3%) and adverse
events (13.6%).Changes in Liver Chemistry
In the total cohort, there was a small increase in liver
enzymes over time (Figure 1). The median ALP gradually
Table 1. Baseline Demographics, Clinical, and Laboratory
Data (n ¼ 102)
Male, n (%) 64 (62.8)
Age at PSC diagnosis,
mean  SD (range), y
31.4  14.2 (11–86)
Age at IBD diagnosis,
mean  SD (range), y
26.0  12.3 (9–62)
Cirrhosis, n (%) 21 (20.6)
Type of PSC, n (%)
Large-duct PSC 92 (90.2)
Small-duct PSC 8 (7.8)
PSC/AIH overlap 2 (2.0)
Type of IBD, n (%)
Ulcerative colitis 66 (64.7)
Crohn’s disease 30 (29.4)
IBD-unspecified 6 (5.9)
UDCA use, n (%) 61 (59.8)
Mean dose  SD (range),
mg/kg/day
13.9  3.7 (5–20.4)
Previous anti-TNF use, n (%) 66 (64.7)
Duration of vedolizumab,
median (range), d
412 (37–2609)
ALP >ULN at baseline, n (%) 69 (67.7)
Baseline laboratory tests,
median (IQR)
Alkaline phosphatase (IU/L  ULN) 1.54 (0.86–2.67)
Alanine transaminase (IU/L) 38 (22–76)
Aspartate transaminase (IU/L) 38 (23–69)
Bilirubin (mmol/L) 10 (6.6–16.0)
Albumin (g/L) 37 (33–41)
Platelets (x106/L) 330 (213–401)
International normalized ratio 1 (0.97–1.12)
Creatinine (mmol/L) 70 (63–80)
Sodium (mmol/L) 139 (137–141)
AIH, autoimmune hepatitis; ALP, alkaline phosphatase; IBD, inflammatory
bowel disease; IQR, interquartile range; PSC, primary sclerosing cholangitis;
SD, standard deviation; TNF, tumor necrosis alpha; UDCA, ursodeoxycholic
acid; ULN, upper limit of normal.
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[ULN]; IQR, 0.86–2.67) to last follow-up (1.64  ULN;
IQR, 1.04–3.47; P ¼ .018), with similar to intermediate
values at Week 6 (1.55  ULN; IQR, 0.82–2.95; P ¼ .084)
and Week 14 (1.64  ULN; IQR, 1.00–3.61; P ¼ .52). A
comparable increase was seen for median ALT (baseline,
38 IU/L; IQR, 22–76 vs last follow-up, 53 IU/L; IQR,
29–100; P ¼ .002), median AST (baseline, 38 IU/L; IQR,
23–69 vs last follow-up, 49 IU/L; IQR, 27–93; P ¼ .0002),
and median bilirubin (baseline, 10 mmol/L; IQR, 7–16 vs
last follow-up, 12 mmol/L; IQR, 8–21; P ¼ .0002).
Twenty-one (20.6%) patients had an ALP drop
20% from baseline to last follow-up. Thirty-nine
patients (38.2%) had a stable ALP, whereas 42 pa-
tients (41.2%) had ALP increase by 20% at last
follow-up (Figure 2). The trajectories of the ALP from
baseline over time are shown in Supplementary
Figure 1.
On univariate analysis, the presence of cirrhosis was
associated with an ALP drop of 20% from baseline to
last follow-up (odds ratio, 4.70; 95% confidence interval,
1.61–13.76) (Table 2). This finding was reproduced onmultivariate analysis. No other variables were associated
with 20% ALP drop, including ursodeoxycholic acid
(UDCA) use at baseline. However, we observed a trend
toward an association with a raised baseline ALP, and
having CD or IBD-unspecified rather than UC. Twenty-
nine percent of female patients and 42.9% of patients
with cirrhosis achieved such drop in ALP compared with
15.6% of males and 13.8% of patients without cirrhosis.
Of note, only 3 of the 21 patients with an ALP drop
20% had a normal ALP at baseline. No variables were
associated with ALP increase 20% from baseline
(Supplementary Table 3).
Refer to Supplementary Results for additional ana-
lyses carried out on specific cohorts, including patients
with cirrhosis, those not on UDCA, those who had been
on vedolizumab for a minimum of 6 months, and those
with baseline ALP >1.5  ULN.
Endoscopic Inflammatory Bowel Disease
Response
Data on endoscopic response to vedolizumab at
baseline and at follow-up were available for 74 pa-
tients. The median duration from vedolizumab initia-
tion to follow-up endoscopy was 227 days (IQR,
130–336; range, 67–2540). Forty-two patients (56.8%)
had an endoscopic IBD response, with the remainder
worsened or unchanged. Normal ALP at baseline and
longer vedolizumab duration were associated with an
endoscopic IBD response, although type of IBD was not
associated (Supplementary Table 6).
Endoscopic scores were available for a subset of
patients (Figure 3). Among patients with UC, the mean
endoscopic scores dropped prevedolizumab versus
postvedolizumab for Mayo Endoscopic Subscore (2.2 
0.8 to 1.4  0.9; P ¼ .0008) and Ulcerative Colitis
Endoscopic Index of Severity (4.2  1.5 to 2.5  2.0;
P ¼ .028). Among patients with CD, Simple Endoscopic
Score for Crohn’s Disease prevedolizumab and post-
vedolizumab was only available for 5 patients and
there was a numerical improvement in mean Simple
Endoscopic Score for Crohn’s Disease (17.0  9.1 to 8.8
 11.0; P ¼ .215).
Safety and Liver-Related Outcomes
Safety and liver-related outcomes were calculated
for the 102 patients described previously, and the 3
patients who had received fewer than 3 vedolizumab
infusions and had follow-up liver biochemistry data (1
infusion [n ¼ 2]) and 2 infusions [n ¼ 1]). Of these 105
patients, a 3-fold elevation in ALP, ALT, and AST from
baseline to last follow-up was observed in 6 (5.7%), 11
(10.4%), and 3 (2.9%) patients; doubling of total bili-
rubin was noted in 21 (20.0%).
Twenty-two patients (20.9%) experienced a liver-
related outcome over the median follow-up period of 561
Figure 1. Change in liver
biochemistry over time on
vedolizumab. The median,
IQR, and range are shown.
The number of patients
with liver biochemistry
values and therefore
included in the analyses
are shown for each time-
point above the corre-
sponding box and
whiskers plot. Wilcoxon
matched-pairs signed rank
test was performed. VDZ,
vedolizumab. ns ¼ P >
.05; *P  .05; **P  .01;
***P  .001.
January 2020 Vedolizumab for PSC-IBD 183days. Twelve patients (11.4%)were listed for LT, ofwhom8
(7.6%) underwent LT. Nine patients (8.8%) experienced at
least 1 episode of cholangitis and 6 patients (5.9%) had
new-onset ascites. No patient experienced a variceal bleed,
nor developed cholangiocarcinoma, and there were no
deaths. On univariate analysis, cirrhosis, baseline ALP>ULN, and baseline albumin level were associated with the
occurrence of a liver-related outcome (Supplementary
Table 7). Among patients with cirrhosis (n ¼ 21), 3/9
(33.3%)of patientswho had anALP drop20%had a liver-
related complication, comparedwith 7/12 (58.3%)who did
not have an ALP drop 20%.
Figure 2. The percentage
change in ALP from base-
line to last follow-up. Each
dot represents an individ-
ual patient (n ¼ 102) and is
color coded to show 3
different groups. Red, ALP
increase by 20%; black,
stable ALP (-20%
to þ20%); blue, ALP drop
by 20%. The black
dotted line at 0 represents
no change, with those
below having a decrease
in ALP at last follow-up
and those above having
an increase in ALP at last
follow-up, as compared
with baseline ALP before
vedolizumab.
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The data presented here, which represent an interna-
tional, multicenter experience, add substantially to the
existing literature on the subject of patients with PSC
exposed to vedolizumab. The demographics of the cohort
closely resembled that reported in the literature, with most
having large-duct PSC, two-thirds having UC, and one-third
CD or IBD-unspecified, a proportion having advanced liver
disease, and just under two-thirds being on UDCA treat-
ment.17,21,22 The median age at PSC diagnosis of 31.4 years
is slightly lower than in the literature (40 years),23 which
may reflect the demographic who have more active IBD orTable 2. Univariate and Multivariate Analysis for ALP Drop by 2
Variable
Univariate
Odds ratio (95% CI)
Cirrhosis 4.70 (1.61–13.76)
Baseline ALP >ULNa 3.53 (0.96–12.98)
Ulcerative colitisb 0.37 (0.12–1.19)
Male gender 0.46 (0.17–1.20)
Age at diagnosis of PSCc 1.03 (0.99–1.06)
UDCA use at baseline 0.68 (0.26–1.79)
Small-duct PSCd 0.55 (0.06–4.74)
PSC-AIH overlapd 3.84 (0.23–64.29)
Duration vedolizumabe 1.04 (0.98–1.09)
IBD improvement on vedolizumabf 1.18 (0.37–3.75)
Previous anti-TNF use 0.63 (0.22–1.83)
AIH, autoimmune hepatitis; ALP, alkaline phosphatase; CI, confidence interval; IBD
necrosis factor; UDCA, ursodeoxycholic acid; ULN, upper limit of normal.
aBaseline indicating last ALP taken before vedolizumab commenced.
bVersus IBD-unspecified or Crohn’s disease.
cPer 1-year increase.
dVersus large-duct PSC.
ePer 1-month increase in vedolizumab duration.
fEndoscopic improvement versus unchanged/worsened.are more likely to receive a biologic therapy. However, one
should keep inmind that this cohort has active IBD,which in
itself is a minority of the PSC demographic, because most
patients with PSC have fairly quiescent IBD, not requiring
biologic therapy (or, 20%–40% do not have IBD at all).5
Therefore, the effect of vedolizumab in PSC with inactive
IBD or no IBD has never been observed or evaluated.
It is immediately apparent that there is heterogeneity
with regard to changes in ALP, an important marker of
cholestasis. The reduction in ALP of20% from baseline in
a subset of treated patients may indicate a biologic effect of
vedolizumab in patients with PSC, although a more pro-
nounced spontaneous fluctuation cannot be excluded. ALP0% or More From Baseline to Last Follow-up
Multivariate
P value Odds ratio (95% CI) P value
.005 4.48 (1.28–15.72) .019
.058 3.39 (0.76–15.25) .111
.096 0.35 (0.10–1.19) .092
.112 0.55 0.17–1.72) .301
.111 1.01 (0.97–1.05) .723
.438 0.55 (0.17–1.78) .318
.585 —
.349 —
.178 —
.777 —
.395 —
, inflammatory bowel disease; PSC, primary sclerosing cholangitis; TNF, tumor
Figure 3. Endoscopic IBD response at baseline endoscopy before vedolizumab and after treatment with vedolizumab. Paired
endoscopic scores were available for 36 patients for Mayo Endoscopic Subscore, 13 patients for UCEIS, and 5 patients for
SES-CD. Individual scores for each patient are shown as black dots, with bars indicating the mean value and the standard
deviation is shown. Paired Student t test performed. SES-CD, Simple Endoscopic Score for Crohn’s Disease; UCEIS, Ul-
cerative Colitis Endoscopic Index of Severity; VDZ, vedolizumab; ns ¼ P > .05; *P  .05; ***P  .001.
January 2020 Vedolizumab for PSC-IBD 185is thought to be a potential surrogate marker for clinical
outcome in PSC, and has been proposed by a panel of ex-
perts as an important endpoint in clinical trials.24 Although
spontaneous normalization of ALP has been described in a
variable proportion of patients with PSC irrespective of
endoscopic intervention or use of UDCA,25 the natural his-
tory of PSC is for the ALP level to remain relatively stable or
increase slightly over time. For instance, in a recent clinical
trial investigating the role of norUDCA on patients with PSC,
the 40 patients on placebo had a mean relative change of
1.2% increase over the 12-week study duration.17 There-
fore, the observed reduction in ALP by20% in a subset of
patients on vedolizumab suggests a possible therapeutic
signal worthy of additional investigation. However, a drop
in ALP does not necessarily correlate with improved clinical
outcome. As seen in the high-dose UDCA trial for patients
with PSC, those on UDCA experienced a significant drop in
ALP as compared with placebo, but developed more liver-
related clinical endpoints.26
In the cohort overall, the median values for ALP, AST,
ALT, and bilirubin all increased from baseline to last
follow-up on vedolizumab. This increase, however, was
small, and may reflect changes commensurate with the
natural history and progression of the disease. Median
ALP rose from 1.54  ULN to 1.64  ULN, which is
equivalent to 184 to 197 IU/L (if ULN ¼ 120 IU/L). This
is itself a clinically insignificant increase, and therefore,
when viewed overall, the increase in ALP is unlikely to
represent a significant safety signal.
The drop in ALP of 20% was associated with
cirrhosis and there was a trend toward an association
with a higher ALP at baseline. Patients with cirrhosis and
those with a raised ALP are potentially more likely tohave a more inflammatory and progressive form of PSC,
and therefore may theoretically benefit more substan-
tially from an anti-inflammatory effect of reduced
migration of lymphocytes to the liver. Furthermore,
vedolizumab is degraded to smaller peptides and amino
acids to be excreted by the kidneys, and this process is
partially done by hepatic proteolytic degradation.27
Cirrhosis may reduce/slow the breakdown of vedolizu-
mab thereby leading to higher serum concentrations,
possibly leading to greater clinical effect.
It is difficult to conclude whether this association of
cirrhosis with ALP reduction 20% is a true finding or a
spurious one. Within that cohort of patients with
cirrhosis, we could not show that changes in ALP
correlated with changes in liver synthetic function, such
as bilirubin and international normalized ratio. In any
case, there was no clear indication that patients with
cirrhosis did worse on vedolizumab, and should a future
prospective trial be carried out in PSC, it would be
important to include patients with compensated
cirrhosis and explore this association further.
Christensen et al28 also observed an association of an
elevated ALP at baseline with subsequent reduction after
treatment with vedolizumab. In their study, when
examining patients with raised ALP at baseline, 11/18
patients (69%) had an ALP drop, with median ALP going
from 475 IU/L at baseline to 322.5 IU/L at Week 14 and
283 IU/L at Week 30. In patients with normal ALP at
baseline, there was a trend for the ALP to increase
slightly. Equally, these findings should be interpreted
with caution, because statistical regression to the mean
may account for the association with a higher ALP at
baseline, and we were unable in this retrospective study
186 Lynch et al Clinical Gastroenterology and Hepatology Vol. 18, No. 1to distinguish hepatic, intestinal, and other isoforms of
ALP.
One fifth of our cohort (22/105) experienced a liver-
related outcome. This may be slightly overrepresented
by the occurrence of cholangitis (8.8%), which in itself,
unless recurrent and refractory to oral antibiotics, is not
necessarily an indication of advanced liver disease
requiring LT. If we exclude those with cholangitis only
(7/9), then 14/102 (13.7%) experienced a liver-related
outcome. These findings are similar to the recently re-
ported trial of anti-LOXL-2 antibody, simtuzumab, in PSC,
where 47/234 patients (20.1%) experienced a PSC-
related event, with an overrepresentation of cholangitis
(n ¼ 31, or 13.2% of total cohort).29 This proportion of
liver-related outcomes is consistent with the natural
history of PSC and does not by itself indicate that
vedolizumab treatment is harmful in PSC.
It is important to highlight the fact that a significant
proportion of patients had an endoscopic IBD response,
both as reported by the treating clinician (42/74 pa-
tients; 56.8%) and by the more robust measure of drop
in individual endoscopic scores (particularly Mayo
Endoscopic Subscore and Ulcerative Colitis Endoscopic
Index of Severity). Such a response rate is similar to that
found in IBD alone.8 Given the possibility that PSC-IBD
represents an immunologically and phenotypically
distinct form of IBD from IBD alone,3-6 this finding is
reassuring for clinicians considering vedolizumab to
treat active IBD in patients with PSC.
A major limitation of this study is its retrospective
nature. The use of objective outcome measures, such as
liver biochemistries and endoscopic scores, serves to
minimize bias; however, adverse events, particular those
not leading to hospitalization, death, or LT could poten-
tially be underreported. In addition, the absence of a
comparator group, such as a placebo-treated, or matched
control cohort, is a weakness that disallows attribution of
causality. Finally, we did not collect information on UDCA
use after baseline. Therefore, some patients might have
started UDCA after starting vedolizumab, which could
conceivably alter the ALP values at follow-up. Never-
theless, we separately examined the subgroup of patients
not on UDCA at baseline, and observed similar changes in
ALP and other liver biochemistries compared with pa-
tients taking UDCA, suggesting that we cannot attribute
the observed changes to the use of UDCA.
In conclusion, this large international experience of
vedolizumab in patients with PSC and IBD shows that a
clear-cut biochemical response to vedolizumab is not
observed across the entire cohort. However, a subset of
patients had a substantial drop in their ALP of 20% or
more. Patients with more aggressive disease, such as the
presence of cirrhosis and potentially those with a raised
ALP at baseline, were more likely to respond. In addition,
the proportion of patients experiencing a liver-related
outcome seems to be in keeping with the natural his-
tory of disease. Furthermore, more than half of patients
with IBD and PSC treated with vedolizumab had anendoscopic IBD response, similar to rates reported in
IBD-only patients, and without an apparent increase in
the discontinuation rate. Despite the disappointment
with lack of a uniform response, further evaluation of
vedolizumab as a beneficial treatment in PSC may be
warranted in a subset of patients via a stratified ran-
domized clinical trial.
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Data Collected
A pro forma detailing the inclusion and exclusion
criteria, baseline demographics, and necessary data for
collection was sent electronically to participating centers,
and data were collated centrally (by KDL). Efforts were
made to collect missing data by electronic correspon-
dence with participating centers. Patients for whom data
were incomplete in respect of treatment or ALP at
baseline and follow-up were excluded from the analysis.
Endoscopic data were provided where available; how-
ever, the lack of endoscopic scoring for IBD before the
start of vedolizumab and at last follow-up was not
regarded as an exclusion criterion.
Baseline demographics collected included gender, age
at diagnosis of PSC, type of PSC, presence of cirrhosis,
type of IBD, race, and ethnicity. The presence or not of
cirrhosis was determined by the treating clinician ac-
cording to clinical parameters, imaging, and liver biopsy
(where available). Whether vedolizumab had been dis-
continued was recorded, as was the reason for discon-
tinuation (if known), the duration of vedolizumab
treatment, baseline UDCA use and dose, and past use of
anti–tumor necrosis factor medication.
Clinical laboratory parameters collected at baseline
and follow-up included serum ALP, ALT, AST, bilirubin
and albumin, platelet count, and international normal-
ized ratio. ALP was measured in international units per
liter and calculated times the ULN. Follow-up laboratory
tests were included up until LT, death, or 56 days
following the final vedolizumab infusion (because this is
the usual duration between maintenance infusions),
whichever occurred first.Time-Points of Liver Biochemistry Data
Liver biochemistry data (ALP, ALT, AST, and bilirubin
levels) were collected at baseline, Week 6 (ie, Day 42),
Week 14 (ie, Day 96), and last follow-up while on
vedolizumab. The time points of Week 6 and Week 14
were used as early and medium time points to assess
change in liver biochemistry because these correspond
with the last induction dose of vedolizumab and the first
maintenance dose time points. In clinical practice, the
response of IBD to vedolizumab treatment is typically
assessed after 6–10 weeks.1,2
Liver biochemistry results were included up until 56
days after the final vedolizumab infusion, because 56
days is the interval between vedolizumab maintenance
doses. For these time point analyses, only patient data
that had paired baseline and the appropriate time point
data were used. To allow for variation in clinical practice,
laboratory test results from Days 30–59 could be
assigned as the Week 6 value, and from Days 90–119
were used for the Week 14 value.Statistical Analyses
In comparing continuous variables from baseline to a
later time point, paired Student t tests or Wilcoxon
matched-pairs signed rank tests were used according to
whether the data were distributed parametrically or
nonparametrically, respectively.
Univariate logistic regression was carried out for
the outcomes of ALP reduction 20% from baseline
to last follow-up, ALP rise 20% or more from
baseline to last follow-up, ALP <1.5  ULN at last
follow-up (within subgroup with baseline ALP
>1.5  ULN), the presence of liver-related outcomes,
and improved endoscopic IBD response (vs wors-
ened/unchanged). Multivariate logistic regression was
carried out to assess the impact of relevant variables
on ALP drop or rise by 20% or more from baseline
to last follow-up. Separate univariate and multivar-
iate logistic regression was carried out on ALP drop
by 20% or more for the cohort of patients who were
not also on UDCA at vedolizumab initiation, because
UDCA use can lower ALP. Where there were missing
covariates, a complete case analysis was carried out
(Supplementary Table 2).
The statistical software used was GraphPad Prism
version 7.0a for Mac OS X (GraphPad Software, La Jolla,
CA, www.graphpad.com), and for the univariate and
multivariate analyses, R 3.5.1 Core Team (R: A language
and environment for statistical computing. R Foundation
for Statistical Computing, Vienna, Austria, 2018. URL
http://www.R-project.org/).
Supplementary Results
Duration of Vedolizumab and Follow-up
The median duration of vedolizumab treatment was
412 days (IQR, 180–651; range, 37–2609), and patients
were followed up with regards to clinical endpoints for a
median duration of 561 days (IQR, 325–790; range,
42–2614). All patients had received a minimum of 3 in-
fusions at the usual dosing schedule, except for 1 patient
whose third infusion was slightly earlier on Day 37
rather than Day 42/Week 6. Forty-four patients (43.1%)
had their vedolizumab treatment stopped during the
study period. Most treatment cessation was caused by
lack of efficacy (32 patients; 72.3%), with 6 (13.6%)
stopping because of an adverse reaction and another 6
stopping for unknown reasons.
Timepoints of Last Follow-up Liver
Biochemistry Variables
The median duration postvedolizumab of the last
follow-up laboratory measurement varied depending on
the biochemistry variable. These were: ALP, 374 days
(IQR, 167–579); ALT, 374 days (IQR, 166–613); AST, 438
January 2020 Vedolizumab for PSC-IBD 187.e2days (IQR, 208–641); and bilirubin, 385 days (IQR,
167–637).
Outcomes on Subsets of Patients
Patients with cirrhosis. Within the cohort of patients
with cirrhosis (n ¼ 21) no correlation was found be-
tween change in ALP and change in other parameters of
liver and organ function, such as international normal-
ized ratio, bilirubin, and creatinine (data not shown).
Patients not on ursodeoxycholic acid. Separate uni-
variate and multivariate analyses were carried out on the
subgroup of patients who were not on UDCA at baseline
(n ¼ 41; Supplementary Table 4). Ten patients (24.4%)
had an ALP drop 20%; cirrhosis again was associated
with this outcome in this cohort on univariate analysis,
but not on multivariate analysis.
Patients with baseline alkaline phosphatase >1.5 3
upper limit of normal. Given the previous evidence for a
worse prognosis in patients whose ALP is >1.5  ULN,20-
22 we also evaluated within the subgroup of patients
whose baseline ALP was >1.5  ULN, looking at the
outcome of the proportion whose ALP dropped to
<1.5  ULN at last follow-up.
When analyzing this subgroup of patients (ALP
>1.5  ULN at baseline; n ¼ 51) 10 (19.6%) had ALP
<1.5  ULN at last follow-up. Univariate analysesrevealed that only type of IBD was associated with this
outcome, with an odds ratio of 0.07 (95% confidence
interval, 0.013–0.39; P ¼ .002) for UC as compared with
CD/IBD-unspecified (Supplementary Table 5).
Patients with duration of vedolizumab >6
months. Seventy-three patients had been on vedolizu-
mab for a minimum of 6 months and had ALP data to
>6 months. We analyzed this subgroup to determine if
a longer duration of vedolizumab treatment had any
bearing on the previously mentioned results. In this
cohort, the median ALP did not change from baseline
(1.65  ULN; IQR, 0.93–3.01) to last follow-up (1.63 
ULN; IQR, 1.03–3.56; P ¼ .284), and a similar pro-
portion of patients had an ALP drop 20% (24.7%)
and ALP rise 20% (37.0%) compared with the
overall cohort. Univariate and multivariate analyses
were also similar to those of the overall cohort (data
not shown).References
1. Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizu-
mab induction therapy for patients with Crohn’s disease in
whom tumor necrosis factor antagonist treatment failed.
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Supplementary Figure 1. The trajectory of ALP from baseline over time according to baseline ALP below and above ULN (n ¼
102). These spaghetti plots show ALP at baseline and different time points on vedolizumab. Each line represents a unique
patient. The dotted black line represents an ALP of 1  ULN. (A) Patients whose baseline ALP was less than 1  ULN. (B)
Patients whose baseline ALP was greater than 1  ULN. The inset in A is a magnified portion of the graph to more easily see
the trajectory of those below the ULN. Vedolizumab was started at Day 0. Patients whose baseline ALP was <ULN tended to
follow a fairly stable course, whereas those with baseline >ULN followed a fairly erratic course.
187.e3 Lynch et al Clinical Gastroenterology and Hepatology Vol. 18, No. 1
Supplementary Table 1. Participating Center and the
Number of Patients From Each
Center Included in the Overall
Cohort (n ¼ 102)
Center Location n
Oxford University Hospitals Oxford, UK 15
Friedrich-Alexander-University Erlangen,
Germany
10
University of Alberta Edmonton,
Canada
10
Academic Medical Center Amsterdam,
Netherlands
7
University Hospitals Birmingham Birmingham, UK 7
University Medical Center Hamburg-
Eppendorf
Hamburg,
Germany
7
University of Miami Miami, FL 6
Massachusetts General Hospital Boston, MA 6
University of California Davis Davis, CA 6
Karolinska Instituet Stockholm,
Sweden
6
University of Washington Medical Center Seattle, WA 4
Yale University School of Medicine New Haven, CT 4
Erasmus Medical Center Rotterdam,
Netherlands
4
University of Copenhagen Copenhagen,
Denmark
3
Medical University of Vienna Vienna, Austria 2
California Pacific Medical Center San Francisco,
CA
1
University of Gothenburg Gothenburg,
Sweden
1
Ospedali Riuniti University Hospital Ancona, Italy 1
University of Padova Padova, Italy 1
Epatocentro Ticino Lugano,
Switzerland
1
Supplementary Table 2. Number of Variables Missing Within
the Complete Dataset (n ¼ 102)
Variable N
Presence of cirrhosis 1
Baseline ALP 0
Type of IBD 0
Gender 0
Age at diagnosis of PSC 0
UDCA use at baseline 0
Type of PSC 0
Duration vedolizumab 0
IBD response 28
Previous anti-TNF use 7
Paired baseline follow-up ALP 0
Paired baseline and follow-up ALT 1
Paired baseline and follow-up
AST
34
Paired baseline and follow-up
bilirubin
5
Baseline platelets 3
Baseline INR 39
Baseline albumin 9
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; IBD, inflammatory bowel disease; INR, international
normalized ratio; PSC, primary sclerosing cholangitis; TNF, tumor necrosis
factor; UDCA, ursodeoxycholic acid.
January 2020 Vedolizumab for PSC-IBD 187.e4
Supplementary Table 3. Univariate and Multivariate Analysis for ALP Rise by 20% or More From Baseline to Last Follow-up
Variable
Univariate Multivariate
OR (95% CI) P value OR (95% CI) P value
Cirrhosis 0.20 (0.02–1.60) .130 0.163 (0.02–1.44) .103
Baseline ALP >ULNa 0.47 (0.16–1.35) .161 0.78 (0.23–2.62) .679
Ulcerative colitisb 2.96 (0.79–11.10) .107 2.66 (0.67–10.54) .165
Male gender 1.52 (0.49–4.72) .466 1.52 (0.45–5.19) .502
Age at diagnosis of PSCc 1.01 (0.97–1.04) .767 1.02 (0.98–1.06) .416
UDCA use at baseline 0.54 (0.19–1.53) .244 0.56 (0.17–1.91) .358
Small-duct PSCd 1.71 (0.31–9.30) .534 —
PSC-AIH overlapd n/ae n/a —
Duration vedolizumabf 1.01 (0.95–1.06) .832 —
IBD improvedg 0.90 (0.24–3.26) .873 —
Previous anti-TNF use 1.53 (0.45–5.18) .492 —
AIH, autoimmune hepatitis; ALP, alkaline phosphatase; CI, confidence interval; IBD, inflammatory bowel disease; n/a, not applicable; OR, odds ratio; PSC, primary
sclerosing cholangitis; TNF, tumor necrosis factor; UDCA, ursodeoxycholic acid; ULN, upper limit of normal.
aBaseline indicating last ALP taken before vedolizumab commenced.
bVersus IBD-unspecified or Crohn’s disease.
cPer 1-year increase.
dVersus large-duct PSC.
eThere were too few numbers of events to fit the binomial generalized linear model, and therefore an OR could not be calculated.
fPer 1-month increase in vedolizumab duration.
gEndoscopic improvement versus unchanged/worsened.
Supplementary Table 4. Univariate and Multivariate Analysis for ALP Drop by 20% or More From Baseline to Last Follow-up
Among Patients Not on Ursodeoxycholic Acid (n ¼ 41)
Variable
Univariate Multivariate
Odds ratio (95% CI) P value Odds ratio P value
Cirrhosis 7.80 (1.60–38.11) .011 5.72 (0.68–47.79) .107
Baseline ALP >ULNa 2.83 (0.62–13.04) .181 2.12 (0.27–16.34) .472
Ulcerative colitisb 0.24 (0.05–1.10) .067 0.41 (0.06–2.92) .370
Male gender 0.42 (0.10–1.81) .245 0.42 (0.06–3.03) .392
Age at diagnosis of PSCc 1.06 (1.00–1.12) .053 1.03 (0.95–1.11) .468
Small-duct PSCd 1.75 (0.14–21.88) .664 —
PSC-AIH overlapd 3.50 (0.20–62.42) .394 —
Duration vedolizumabe 1.06 (0.98–1.14) .157 —
IBD improvedf 0.75 (0.14–4.13) .741 —
Previous anti-TNF use 0.83 (0.19–3.75) .812 —
AIH, autoimmune hepatitis; ALP, alkaline phosphatase; CI, confidence interval; IBD, inflammatory bowel disease; PSC, primary sclerosing cholangitis; TNF, tumor
necrosis factor; ULN, upper limit of normal.
aBaseline indicating last ALP taken before vedolizumab commenced.
bVersus IBD-unspecified or Crohn’s disease.
cPer 1-year increase.
dVersus large-duct PSC.
ePer 1-month increase in vedolizumab duration.
fEndoscopic improvement versus unchanged/worsened.
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Supplementary Table 5. Univariate Analysis for ALP <1.5 
ULN at Last Follow-up, Among
Subgroup of Patients for Whom
Baseline ALP >1.5  ULN (n ¼ 51)a
Variable
Univariate
OR (95% CI) P value
Cirrhosis 0.62 (0.11–3.38) .576
Ulcerative colitisb 0.07 (0.01–0.39) .002
Male gender 0.34 0.08–1.43) .142
Age at diagnosis of PSCc 1.02 (0.97–1.08) .434
UDCA use at baseline 2.56 (0.48–13.62) .270
Small-duct PSCd n/ae n/a
PSC-AIH overlapd n/ae n/a
Duration vedolizumabf 1.04 (0.95–1.13) .411
IBD improvedg 0.92 (0.17–4.86) .925
Previous anti-TNF use 0.30 (0.07–1.33) .112
AIH, autoimmune hepatitis; ALP, alkaline phosphatase; CI, confidence interval;
IBD, inflammatory bowel disease; n/a, not applicable; OR, odds ratio; PSC,
primary sclerosing cholangitis; TNF, tumor necrosis factor; UDCA, ursodeox-
ycholic acid; ULN, upper limit of normal.
aBaseline indicating last ALP taken before vedolizumab commenced.
bVersus IBD-unspecified or Crohn’s disease.
cPer 1-year increase.
dVersus large-duct PSC.
eThere were too few numbers of events to fit the binomial generalized linear
model, and therefore an OR could not be calculated.
fPer 1-month increase in vedolizumab duration.
gEndoscopic improvement versus unchanged/worsened.
Supplementary Table 6. Univariate Analysis for Endoscopic
IBD Response (n ¼ 74)
Variable
Univariate
OR (95% CI) P value
Cirrhosis 0.79 (0.27–2.35) .677
Baseline ALP >ULNa 0.29 (0.10–0.85) .024
Ulcerative colitisb 1.01 (0.39–2.61) .979
Male gender 1.12 (0.43–2.90) .815
Age at diagnosis of PSCc 1.01 (0.97–1.05) .635
UDCA use at baseline 2.57 (0.97–6.81) .058
Small-duct PSCd 1.15 (0.18–7.35) .880
PSC-AIH overlapd n/ae n/a
Duration vedolizumabf 1.08 (1.02–1.14) .013
Previous anti-TNF use 1.47 (0.53–4.08) .456
AIH, autoimmune hepatitis; ALP, alkaline phosphatase; CI, confidence interval;
IBD, inflammatory bowel disease; n/a, not applicable; OR, odds ratio; PSC,
primary sclerosing cholangitis; TNF, tumor necrosis factor; UDCA, ursodeox-
ycholic acid; ULN, upper limit of normal.
aBaseline indicating last ALP taken before vedolizumab commenced.
bVersus IBD-unspecified or Crohn’s disease.
cPer 1-year increase.
dVersus large-duct PSC.
eThere were too few numbers of events to fit the binomial generalized linear
model, and therefore an OR could not be calculated.
fPer 1-month increase in vedolizumab duration.
Supplementary Table 7. Univariate Analysis for Liver-
Related Outcome (n ¼ 102)a
Variable Odds ratio P value
Cirrhosis 5.70 (1.96–16.57) .001
Baseline ALP >ULNb 1.67 (1.23–2.28) .001
Ulcerative colitisc 1.12 (0.40–3.08) .833
Male gender 1.63 (0.57–4.65) .358
Age at diagnosis of PSCd 0.99 (0.96–1.03) .696
Baseline serum albuminb,e 0.90 (0.83–0.98) .024
Baseline plateletsb,f 0.96 (0.92–1.00) .051
Baseline INRb,g 1.28 (0.84–1.95) .251
ALP, alkaline phosphatase; IBD, inflammatory bowel disease; INR, international
normalized ratio; LT, liver transplantation; PSC, primary sclerosing cholangitis;
ULN, upper limit of normal.
aLiver-related outcome defined as any of the following: listing for LT, under-
going LT, ascending cholangitis, new-onset ascites, variceal bleed, chol-
angiocarcinoma, and death.
bBaseline indicating last laboratory value taken before vedolizumab
commenced.
cVersus IBD-unspecified or Crohn’s disease.
dPer 1-year increase.
ePer 1 mg/L increase.
fPer 10  109/L increase.
gPer 0.1-units increase.
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